03 Sep The Effects of Amniotic Stem Cells on Nonischemic Dilated Cardiomyopathy
The Effects of Amniotic Stem Cells on Nonischemic Dilated Cardiomyopathy
Amniotic stem cells, also called mesenchymal stem cells, have shown promising results in the treatment of cardiac diseases. These effects are due to the cell’s ability to transform into damaged cells for the purpose of repairing tissue. As we age, the stem cells produced by our bodies that are responsible for healing are produced by the bone marrow in fewer numbers. This is why it can be much harder to heal.
For patients suffering from nonischemic dilated cardiomyopathy, research has shown that treating with the allogeneic cells derived from a donor is more effective than the autologous cells from one’s own bone marrow. However, both have their advantages and disadvantages. This is according to the POSEIDON-DCM study.
The NHLBI-funded POSEIDON-DCM study assigned over 30 patients with an average age of 56 years old and made up of approximately 30 percent women to either the autologous or allogeneic therapy groups. The results were as researchers had predicted.
Pros and Cons of Both Methods
Dr. Joshua M. Hare, one of the researchers, said that it would make sense that the allogeneic cells would have superior qualities. It’s because the stem cells are derived from amniotic tissues that are young and strong. Because the bone marrow produces fewer stem cells over time, using a patient’s own stem cells wasn’t nearly as effective. Amniotic tissues contain a high concentration of stem cells.
Furthermore, amniotic stem cell therapy is safe, as studies haven’t revealed serious adverse reactions. The most serious adverse reaction has been small nodules around the injection site, but they are mild and go away quickly. There may also be slight irritation at the site of the injection. So far, amniotic stem cell therapy for cardiomyopathy and a wide range of conditions have proven to be safe.
Potential Advancements in Stem Cell Therapy
More research studies will indicate exactly what kind of effect amniotic stem cells have on nonischemic dilated cardiomyopathy. This is important because the condition is very common, particularly in older people. The hope of researchers is that the POSEIDON-DCM study and other studies will result in a FDA-approved therapy.
One of the additional studies currently taking place is being conducted by the Affiliated Hospital of Academy of Military Medical Sciences, and it could reveal a lot about amniotic stem cell therapy and its effect on ischemic cardiomyopathy. The study began in May 2015, was last updated in March 2016, and is expected to conclude in December 2018. The Ivy Institute of Stem Cells Co. Ltd is collaborating on this study.
All in all, amniotic stem cell therapy is showing a lot of promise in the treatment of nonischemic dilated cardiomyopathy and other cardiac conditions. In fact, amniotic stem cell therapy has already become one of regenerative medicine’s most positive steps. It is ethical, safe, and not overly invasive. It’s possible that this type of stem cell therapy could eliminate the need for certain types of heart surgeries and invasive treatments.